Back to Stocks

PALI

PALISADE BIO, INC.
2 filings tracked
healthcarebiotechnologyMICRO (<$300M)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Palisade Bio has transitioned into a well-capitalized clinical-stage entity, boasting a cash reserve of $132.6 million following its October 2025 offering.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite a substantial cash balance, Palisade Bio is facing a sharp escalation in its quarterly cash burn, which surged to $3.9 million in the most recent period.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every PALI filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a company at a pivotal crossroads, balancing a strong immediate liquidity position against a rapidly increasing burn rate. The primary tension for investors lies in whether the $132.6 million cash reserve is sufficient to carry the company through the binary risk of Phase 2 readouts without further massive dilution. While the clinical signals from the Phase 1b FSCD cohort are promising, they remain preliminary and based on a very limited sample size. Ultimately, the impact of this filing is the establishment of a clear catalyst calendar for 2026, including the FDA IND submission and the start of Phase 2 trials. The ability of management to remediate its long-standing internal control weaknesses and successfully transition from exploratory cohorts to large-scale efficacy trials will determine if Palisade can convert its current cash advantage into sustainable clinical value.

Selected Quarter

Core Takeaway

Palisade has secured enough capital to reach major 2027-2028 milestones, but is burning cash faster as it enters larger clinical phases.

Investor Lens

The trade-off is between the high-conviction clinical potential of a targeted PDE4 inhibitor and the risk of further dilution if Phase 2 costs exceed projections.

Watch Next

FDA IND submission for Phase 2 UC and CD studies in Q2 and H2 2026.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.07Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 12

Completed October 2025 offering for net proceeds of $127.6 million, securing long-term runway.

capital raise
90%
bearishMay 12

R&D expenses surged from $0.95M to $6.4M year-over-year due to clinical trial acceleration.

margin compression
70%
neutralMay 12

Continuing material weakness in internal controls over financial reporting since 2021.

regulatory action
50%
bullishMay 12

Completed October 2025 offering for net proceeds of $127.6 million, securing long-term runway.

capital raise
90%
bearishMay 12

R&D expenses surged from $0.95M to $6.4M year-over-year due to clinical trial acceleration.

margin compression
70%
neutralMay 12

Continuing material weakness in internal controls over financial reporting since 2021.

regulatory action
50%

Filing History

10-QMay 12, 2026
Expand Sequence

The Q1 2026 filing presents a company at a pivotal crossroads, balancing a strong immediate liquidity position against a rapidly increasing burn rate. The primary tension for investors lies in whether the $132.6 million cash reserve is sufficient to carry the company through the binary risk of Phase 2 readouts without further massive dilution. While the clinical signals from the Phase 1b FSCD cohort are promising, they remain preliminary and based on a very limited sample size. Ultimately, the impact of this filing is the establishment of a clear catalyst calendar for 2026, including the FDA IND submission and the start of Phase 2 trials. The ability of management to remediate its long-standing internal control weaknesses and successfully transition from exploratory cohorts to large-scale efficacy trials will determine if Palisade can convert its current cash advantage into sustainable clinical value.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.